Assoc. Prof. Mustafa Güzel

Dr. Güzel graduated from Hacettepe University School of Engineering with a B. Sc degree in Chemistry in 1987 and completed his M. Sc. and Ph. D. Degrees on Medicinal Chemistry at Clemson University, Clemson, SC in 1996 and 2001 respectively. He worked as organic lab coordinator at Northeastern University and later joined to ArQule Inc.as Sr. Synthetic Organic Chemist upon his graduation. He then joined to TransTech Pharma Inc, in High Point, NC and assumed various positions in Medicinal Chemistry Department between 2001-2014. He recently joined to International School of Medicine in Department of Medical Pharmacology at Medipol University and currently leading the Division of Molecular Discovery and Development laboratory.

RESEARCH INTERESTS

    • Research and development in medicinal chemistry specifically cancer/cancer metabolism and kinase inhibitors, GPCRs for the treatment of diabetic disorders (NIDDM), obesity, CNS and neurodegenerative disorders (ALS, Alzheimer’s and Parkinson’s disease), and inflammatory disorders (COPD, RA).

      Projects involved;

      • Novel Ghrelin Antagonists for treatment of Obesity.
      • Novel Sigma-1 Receptor Agonists for treatment of Neurodegenerative Diseases.
      • Novel A2A Adenosine Receptor Antagonists for the Treatment of Parkinson’s disease and SAR of the new Preladenant analogs.
      • Discovery of novel Excitatory Amino Acid Transporter-2 (EAAT2) modulators for the treatment of ALS and other neurodegenerative disorders.
      • Regulation of cancer cell metabolism: Targeting cancer metabolism as an alternative therapeutic treatment.
      • Novel therapeutic agents for treatment of diabetes (T2DM).
      • Process development of novel therapeutic agents; cost effective and green chemistry applications for drug discovery.
      • Fluorinated novel VEGF inhibitors for cancer treatment.
    • Research and development with an emphasis in design and synthesis of both symmetric and asymmetric organic drug-like molecules leading to new drug substances and natural products. Discovery of drugs to treat unmet medical needs in the world.
    • Elucidation of the catalytic asymmetric induction reactions and their mechanisms, development of new enantioselective catalysts and their applications in the synthesis of biologically active agents.

PATENTS AND PUBLICATIONS

    • “Induction of Heme Oxygenase I (HMOX1) by HPP-4382: A novel modulator of Bach-1 activity”; Otis Attucks, Kimberly Jasmer, Mark Hannink, Jareer Kassis, Zhenping Zhong, Suparna Gupta, Sam Victory, Mustafa Guzel, Dharma Polisetti, Robert Andrews, Adnan Mjalli, and Matthew Kostura; PLoSOne, 9, 7, (2014), p:1-12, e101044.
    • “Synthesis of Azabridged Bicyclic Ring Systems by Intramolecular Sakurai Reactions”; Mustafa Guzel, Robert Smitherman, and Sezgin Kiren; Tetrahedron Letters, manuscript submitted, 2014.
    • “Substituted Pyran Derivatives Useful as Antitumor Agents”; Mustafa Guzel, Devi Reddy, Rongyuan Xie, Dharma R. Polisetti, Stephen Davis, Soumya Sahoo, Hassan El Abdelloui, and Adnan M. M. Mjalli; High Point Pharmaceuticals Inc., High Point, NC, Patent #US 61/892,053, 2013.
    • “Substituted Fused Oxazoline Derivatives Useful as Antitumor Agents”; Mustafa Guzel, Devi Reddy, Rongyuan Xie, Dharma R. Polisetti, Soumya Sahoo, Stephen Davis, Mohan Rao, Kalpathy Santhosh, and Adnan M. M. Mjalli; High Point Pharmaceuticals Inc., High Point, NC, Patent #US 61/892,018, 2013.
    • “Characterization and application of molecular binary mixed molecular micelles of sodium10-undecenyl sulfate and sodium N-undecenyl leucinate as pseudostationary phases in micellar electrokinetic chromatography”; Cevdet Akbay, Hamid H. Ahmed, Hakan Arslan, Brittany Graham, and Mustafa Guzel; Talanta, 99, (2012), 441-449.
    • ” Study of chemical selectivity of binary mixed micelles of sodium 10-undecenyl sulfate and sodium N-undecenyl leucinate using linear solvation energy reletionships model”; Hamid H. Ahmed, David M. Ahlstrom, Hakan Arslan, Mustafa Guzel, and Cevdet Akbay; Journal of Chromatography A, 1236, (2012), 207-214.
    • “Novel Anticancer agents for hexokinase inhibition-Substituted cyclic-3-indole derivatives”; Mustafa Guzel, Rongyuan Xie, Dharma R. Polisetti, Robert C. Andrews, Adnan M. M. Mjalli, and Stephen Davis; High Point Pharmaceuticals Inc., High Point, NC, Application No: HPP 3018.001 US; patent manuscript submitted, 2013.
    • “Substituted Benzimidazole Derivatives and Methods of Use to Treat Oxidative Stress”; Mustafa Guzel, Sam Victory, Dharma R. Polisetti, Mathew Kostura, Adnan M. M. Mjalli, Otis Attucks, and Jareer Kassis; High Point Pharmaceuticals Inc., High Point, NC, Application No: HPP 3007.000 US; patent manuscript submitted, 2012.
    • “Substituted Pyridine derivatives, Pharmaceutical Compositions, and Methods of Use to Treat Oxidative Stress”; Mustafa Guzel, Sam Victory, Bapu Gaddam, Dharma R. Polisetti, Mathew Kostura and Adnan M. M. Mjalli; High Point Pharmaceuticals Inc., High Point, NC, Patent # WO 2011/022216, (02, 24, 2011).
    • “Oxadiazoanthracene Compounds, for Treatments of Diabetes”; Scott T. Yokum, Mustafa Guzel, Kalpathy C. Santhosh, Dharma R. Polisetti, Daniel P. Christen, Adnan M. Mjalli, and Stephen T. Davis; TransTech Pharma Inc., High Point, NC, , Patent # US 2011/7906507 (03, 15, 2011).
    • “In Silico Ligand-Receptor Docking of Potentially Selective Butyrylcholinesterase Inhibitors Structurally Related to the Marine Natural Product Debromoflustramine B”; Miguel O. Mitchell, Robert W. Figliozzi and Mustafa Guzel;Medicinal Chemistry, Volume 6, Number 3, 2010, Pp. 141-143.
    • “Substituted Pyridine derivatives, Pharmaceutical Compositions, and Methods of Use to Treat Oxidative Stress”; Mustafa Guzel, Sam Victory, Bapu Gaddam, Dharma R. Polisetti, Mathew Kostura and Adnan M. M. Mjalli; High Point Pharmaceuticals Inc., High Point, NC, Patent # US 2010/044508, (05, 08, 2010).
    • “Mandelic Acid Derivatives and Preparation Thereof”; Mustafa Guzel, Scott T. Yokum, and Dharma R. Polisetti; TransTech Pharma Inc., High Point, NC, Patent # US 2010/0036150, (02,11, 2010).
    • “Oxadiazoanthracene Compounds, Compositions of Oxadiazoanthracene Compounds and Methods of Treatment Using the Same”; Scott T. Yokum, Mustafa Guzel, Kalpathy C. Santhosh, Dharma R. Polisetti, Daniel P. Christen, Adnan M. Mjalli, and Stephen T. Davis; TransTech Pharma Inc., High Point, NC, , Patent # US 2010/0324033 (12, 23, 2010).
    • “Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof”; Mustafa Guzel, Scott T. Yokum, Kalpathy C. Santhosh, Dharma R. Polisetti, Chris Behme, Adnan M. Mjalli, and Stephen T. Davis”; TransTech Pharma Inc., High Point, NC, Patent # WO 2010/4824 (07, 10, 2010).
    • “Tricyclic Compounds as Modulators of TNF- Synthesis”; Mustafa Guzel, Mathew Kostura, Adnan M. Mjalli, Bapu Gaddam, and Dharma R. Polisetti; TransTech Pharma Inc., High Point, NC, Patent # US 2010/0190808 (07, 29, 2010).
    • “Oxadiazoanthracene Compounds, for Treatments of Diabetes”; Scott T. Yokum, Mustafa Guzel, Kalpathy C. Santhosh, Dharma R. Polisetti, Daniel P. Christen, Adnan M. Mjalli, and Stephen T. Davis; TransTech Pharma Inc., High Point, NC, , Patent # WO 2009/111700 (11, 09, 2009).
    • “Aryl Carbonyl Derivatives as Therapeutic Agents-Part-II”; Kalpaty C. Santhosh, Mustafa Guzel, Dharma R. Polisetti, Adnan M. Mjalli, and Robert C. Andrews; TransTech Pharma Inc., High Point, NC, Patent # US 2009/7541373 (06, 02, 2009).
    • “Tricyclic Compounds as Modulators of TNF- Synthesis as PDE4 Inhibitors”; Mustafa Guzel, Mathew Kostura, Adnan M. Mjalli, Bapu Gaddam, and Dharma R. Polisetti; TransTech Pharma Inc., High Point, NC, Patent # WO 2009/094528, (07, 30, 2009).